BeiGene promotes Lai Wang; plus Prothena, Myovant and Iveric 

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) promoted Lai Wang to global head of R&D from SVP global research, clinical operations & biometrics, and Asia-Pacific clinical development. Wang joined the oncology play in 2011 as head of discovery biomarkers and in vivo pharmacology.

Neurodegenerative disorder company Prothena Corp. plc (NASDAQ:PRTA) hired Hideki Garren as CMO. Garren was VP global head of neuro-immunology at Roche (SIX:ROG; OTCQX:RHHBY), where he led Phase III development of Ocrevus ocrelizumab to treat multiple sclerosis and Enspryng satralizumab to treat neuromyelitis optica spectrum disorder...